In Queensland Health the Pathology Queensland iSTAT 1® network has grown to over 400 000 patient episodes per year equating to about 1.3 million individual tests. One key factor in the success of the Queensland Health’s State-wide Point of Care Testing network is the centralised management of patient results data and operator management. In 2014 the HemoCue WBC Diff was introduced, with limited connectivity. The HemoCue WBC Diff device provides a larger haematology capability to the network. 29 remote sites are using the device with reasonable outcomes for screening febrile illnesses or acute pain. In the network there are also 4 sites applying the benefits of point of care haematology in Clozapine Clinics. Active quality surveillance has shown results in remote clinics are reflective of the patient’s presentation and have acceptable correlation to paired laboratory tests.